Michael J Goldblatt

7964708, Jun 21, 2011

Nov 15, 2007

11/940714

Limin Li - Bethesda MD, US
Michael Kinch - Laytonsville MD, US
Michael Goldblatt - McLean VA, US
Roxanne Duan - Bethesda MD, US

A61K 35/00
C12N 15/85

5303881, 424 931, 4353261

The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.

7981410, Jul 19, 2011

Nov 13, 2007

11/939122

Roxanne Duan - Bethesda MD, US
Michael Kinch - Laytonsville MD, US
Michael Goldblatt - McLean VA, US

Functional Genetics, Inc. - Gaithersburg MD

A61K 48/00
C07K 16/00

424 931, 5303871

The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein likeTsg 101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface, budding of viral particles is inhibited. The virus infects the initial cells, but cannot escape that cell to infect the body en masse.

8361792, Jan 29, 2013

May 11, 2010

12/777417

Roxanne Duan - Bethesda MD, US
Michael Goldblatt - McLean VA, US

Functional Genetics, Inc. - Gaithersburg MD

C12N 5/07

435327

The invention reflects enhanced antibody expression of an antibody of interest by cell lines transformed by random homozygous gene perturbation methods to either increase or decrease the expression pattern of a gene of the cell line other than the antibody of interest. The transformed cell line exhibits specific productivity rates, SPR, for the RHGP transformed cell liens of 1. 5 or more, as compared with the antibody expressing cell line parents prior to transformation by RHGP. A knock out or anti-sense construct may be devised to reduce expression of the target gene, a promoter may be inserter to enhance expression of the target gene. The antibodies expressed by the transformed cell lines exhibit the binding properties of their parent cell lines prior to transformation with RHGP, and increase Total Volumetric Production of said antibody by said cells in a given volume.

8535684, Sep 17, 2013

Jan 6, 2010

12/652877

Michael S. Kinch - Laytonsville MD, US
Michael Goldblatt - McLean VA, US
Douty Bamba - Randallstown MD, US
Shaojing Chang - Rockville MD, US
Huosheng Chen - Germantown MD, US
Zenbework Fesseha - Columbia MD, US
Manu Kohli - Dunn Loring VA, US
Hanwen Mao - Annandale VA, US
Heather Thi Thu Ung-Medoff - Gaithersburg MD, US
Ke Weng - Gaithersburg MD, US

Functional Genetics, Inc. - Gaithersburg MD

A61K 39/21
A61K 49/00
A61K 39/395
A61K 39/42

4242081, 424 91, 4241301, 4241481

A method for identifying host genes and encoded proteins for potential targets for therapeutic intervention employs a Gene Search Vector that is either lentivirus or MMLV-based, and can be used to interrogate an entire cell genome without prior knowledge of the genomic sequence. This Random Homozygous Gene Perturbation (RUGP) technique is rapidly verifiable and is used to identify potential host targets for intervention for influenza, HIV and other viral infections. Using Thermal Assymetric Interlaced (TAIL)-PCR, the period for identification of promising targets is reduced from months to weeks or less. Specific targets including PTCH1, Robo1 and Nedd4 are reviewed in detail.

8207209, Jun 26, 2012

Oct 23, 2008

12/256571

Michael Kinch - Laytonsville MD, US
Michael Goldblatt - McLean VA, US

Functional Genetics, Inc. - Gaithersburg MD

A61K 31/4184

514394

A method of inhibiting viral respiratory infection in a mammal in need of same, includes administering an effective amount of 2-[2-(5-carbamimidoyl-benzofuran-2-yl)-vinyl]-H-benzoimidazole-5-carboxamidine or the Bis-N-hydroxyamidine prodrug thereof, prior to viral infection, or therapeutically following viral infection, to inhibit that viral infection. The compound selectively inhibits Caspase 2 and/or 8 as to prevent infective viral particle release. It is optionally administered IV, IP, orally or via other conventional administration routes in a dosage range of 1 ng/kg-200 mg/kg of body weight.

20090136927, May 28, 2009

Oct 30, 2007

11/928393

Roxanne Duan - Bethesda MD, US
Michael Goldblatt - McLean VA, US

Functional Genetics, Inc. - Gaithersburg MD

C12Q 1/68
C12N 5/06

435 6, 435326

The invention reflects enhanced antibody expression of an antibody of interest by cell lines transformed by random homozygous gene perturbation methods to either increase or decrease the expression pattern of a gene of the cell line other than the antibody of interest. The transformed cell line exhibits specific productivity rates, SPR, for the RHGP transformed cell liens of 1.5 or more, as compared with the antibody expressing cell line parents prior to transformation by RHGP. A knock out or anti-sense construct may be devised to reduce expression of the target gene, a promoter may be inserter to enhance expression of the target gene. The antibodies expressed by the transformed cell lines exhibit the binding properties of their parent cell lines prior to transformation with RHGP, and increase Total Volumetric Production of said antibody by said cells in a given volume.

20090285819, Nov 19, 2009

Nov 15, 2007

11/940418

Limin Li - Bethesda MD, US
Michael Kinch - Laytonsville MD, US
Michael Goldblatt - McLean VA, US

Functional Genetics, Inc. - Gaithersburg MD

A61K 39/395
A61K 31/7088
A61K 39/00
C07K 16/18

4241391, 4241301, 4241841, 5303879

Genes relating to resistance to infection by influenza virus are identified. The genes and the gene products (i.e., the polynucleotides transcribed from and polypeptides encoded by the genes) can be used for the prevention and treatment of influenza. The genes and the gene products can also be used to screen agents that modulate the gene expression or the activities of the gene products.

20100035925, Feb 11, 2010

Aug 12, 2009

12/539741

Michael Goldblatt - Gaithersburg MD, US
Michael S. Kinch - Gaithersburg MD, US
Limin Li - Potomac MD, US

FUNCTIONAL GENETICS, INC - Gaithersburg MD

A61K 31/4706
A61P 31/18

514313

Compounds that possess anti-infective activity are described. Methods of using these compounds for the treatment or prevention of infectious diseases such as acquired immunodeficiency syndrome (AIDS) are also described. The compounds inhibit HIV infectivity and do not exhibit significant cytotoxicity in HIV producing cells.